Chair: Dr Binodh DeSilva
Vice-Chairs: Dr Michael Ward (Australia) and Dr Hanns-Christian Mahler (Switzerland)
The FIP Biotechnology SIG is comprised of members from many diverse backgrounds in industry and academia and is dedicated to the discovery, development, and manufacturing of biotechnology-related pharmaceutical products and therapies through advances in science and technology. The Biotechnology SIG will provide a dynamic international forum for the exchange of biotechnology-related knowledge among scientists of all disciplines to enhance their contributions to global health. The Biotechnology SIG will offer timely biotechnology-related scientific programs, ongoing education for scientists both new and tenured to the field, as well as opportunities for networking and professional development.
The successful pharmaceutical advancement of biotechnology-related drugs requires cross-functional input from many diverse fields. The SIG will examine both pharmaceutical progress as well as development challenges related to pharmaceutical Biotechnology in areas, including (but not limited to):
- Bioanalytical Methods (e.g., Ligand Binding Assays)
- Biosimilars / Biobetters
- Biotherapeutics ADME
- Cell Therapy Products
- Nucleic Acid Based Therapeutics
- Protein Aggregation and Biological Consequences
- Protein Optimisation
- Therapeutic Protein Immunogenicity
- Translational Medicine
For more information on this SIG, please contact Dr DeSilva at Biotechnology@fip.org.